

# Author Index to Volume 33

- ADALAR N. see Bayraktar M.
- ADAMI S., MIAN M., BERTOLDO F., ROSSINI M., JAYAWERRA P., O'RIORDAN J.L.H. & LO CASCIO V. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment, 391
- ADAMS C.B.T. see Burke C.W.
- ADAMS J. see Hague W.H.
- ADAMS J.E. see Whitehouse R.W.
- AHMED S.R. see Little M.D.
- AKALIN S. see Bayraktar M.
- AKBARI M.T., FITCH N.J., FARMER M., DOCHERTY K., SHEPPARD M.C. & RAMSDEN D.B. Thyroxine-binding prealbumin gene polymorphism: a population study, 155
- ALAGHBAND-ZADEH J. see Holly J.M.P.
- ALLEN M. see Kujala U.M.
- ALFORD F.P. see Pestell R.G.
- ALLOLIO B. see Schulte H.M.
- ALLOLIO B., HOFFMAN J., LINTON E.A., WINKELMANN W., KUSCHE M. & SCHULTE H.M. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone, 279
- ALNASSER H.M.I. see Gadir A.A.
- ALONEZI O.M. see Gadir A.A.
- ALRASHID A.H. see Gadir A.A.
- ANDERSEN H.Ø., JØRGENSEN P.E., BARDHAM L. & HILSTED L. Screening for multiple endocrine neoplasia type 1 in patients with recognized pituitary adenoma, 771
- ANDERSEN M.A. see Pasieka J.L.
- ANDREWS M.A. see Johnson M.R.
- ANG V.T.Y. see Page S.R.
- ARENDE J. see Bojkowski C.J.
- ASAWA T. see Takasu N.
- ASTORGA R. see Leal-Cerro A.
- ÅSTRÖM C., PEDERSEN S.A. & LINDHOLM J. The influence of growth hormone on sleep in adults with growth hormone deficiency, 495
- BAIRD D.T. see Illingworth P.J.
- BAIRD D.T. see Reddi K.
- BALDUCCI R. & TOSCANO V. Bioactive and peripheral androgens in prepubertal simple hypertrichiosis, 407
- BANCROFT K. see Whitehouse R.W.
- BARDHAM L. see Andersen H.Ø.
- BARNETT P.S., DAWSON J.M., BUTLER J., COSKERAN P.B., MACCABE J.J. & MCGREGOR A.M. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man, 307
- BAYRAKTAR M., GEDIK O., AKALIN S., USMAN A., ADALAR N. & TELATAR F. The effect of radioactive iodine treatment on thyroid C cells, 625
- BEARD R.W. see Mason H.D.
- BEARDWELL C.G. see Little M.D.
- BEHRE H.M. see Jockenhövel F.
- BENKER G., RAIDA M., OLBRICHT T., WAGNER R., REINHARDT W. & REINWEIN D. TSH secretion in Cushing's syndrome: relation to glucocorticoid excess, diabetes, goitre, and the 'sick euthyroid syndrome', 777
- BENSO L. see Loche S.
- BERNHARD G. see Kahaly G.
- BERTOLDO F. see Adami S.
- BESSER G.M. see Ross R.J.M.
- BEST J.D. see Pestell R.G.
- BEVAN J.S. see Burke C.W.
- BEYER J. see Kahaly G.
- BODINI C. see Giustina A.
- BOGHEN M. see Loche S.
- BOJKOWSKI C.J. & ARENDT J. Factors influencing urinary 6-sulphatoxymelatonin, a major melatonin metabolite, in normal human subjects, 435
- BORNSTEIN R. see Shoham (Schwartz) Z.
- BOSSONI S. see Giustina A.
- BOULTWOOD J., WYNFORD-THOMAS D., RICHARDS G.P., CRAIG R.K. & WILLIAMS E.D. In-situ analysis of calcitonin and CGRP expression in medullary thyroid carcinoma, 381
- BRAIN C.E. see Suri D.
- BREMNER W.J. see Nakajima S.T.
- BROOKS A. see Pirke K.M.
- BROOK C.G.D. see Hague W.H.
- BROOK C.G.D. see Suri D.
- BROOK C.G.D. The management of classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency, 559
- BROUTIN F. see Estour B.
- BROWN V. see Graf M.J.
- BROWNELL J. see Van't Verlaat J.W.
- BROWNLIE B.E.W. & WELLS J.E. The epidemiology of thyrotoxicosis in New Zealand: incidence and geographical distribution in North Canterbury, 1983–1985, 249
- BULLEN H. see Lunt H.

- BURKE C.W., ADAMS C.B.T., ESIRI M.M., MORRIS C. & BEVAN J.S. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome?, 525
- BUTLER J. see Barnett P.S.
- CALAZEL C. see Caron Ph.
- CAPPA M. see del Balzo P.
- CARON PH., CALAZEL C., PARRA H.J., HOFF M. & LOUVET J.P. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy, 519
- CARTER G.D. see Holly J.M.P.
- CARUSO E. see Schettini G.
- CASANUEVA F.F. see Leal-Cerro A.
- CASANUEVA F.F. see Peñalva A.
- CELLA S.G. see Loche S.
- CHAILURKIT L-O. see Rajatanavin R.
- CHAN J.C.N. see Chow C.C.
- CHARD T. see Holly J.M.P.
- CHARD T. see Iles R.K.
- CHOW C.C., LAI K.N., LEUNG J.C.K., CHAN J.C.N. & COCKRAM C.S. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy, 317
- CHRISTENSEN S.B. see Lundgren E.
- CIANFARANI S. see Holly J.M.P.
- CICCARELLI E. see Ross R.J.M.
- CLIFTON D.K. see Nakajima S.T.
- COCKRAM C.S. see Chow C.C.
- COHEN N.L. see Nakajima S.T.
- COHN M. see Kennedy R.L.
- COLAO A. see Schettini G.
- COMPSTON J.E. Review: Osteoporosis, 653
- CONWAY G.S., JACOBS H.S., HOLLY J.M.P. & WASS J.A. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein I in the polycystic ovary syndrome, 593
- COOPER W. see Donnet M.L.
- CORDA R. see Loche S.
- CORDIDO F. see Leal-Cerro A.
- COSKERAN P.B. see Barnett P.S.
- CRAIG R.K. see Boultonwood J.
- CRONIN C., IGOE D., DUFFY M.J., CUNNINGHAM S.K. & MCKENNA T.J. The overnight dexamethasone test is a worthwhile screening procedure, 27
- CROSBY S.R. see Page S.R.
- CROUGHS R.J.M. see Van't Verlaat J.W.
- CUNNINGHAM S.K. see Cronin C.
- DARNE J. see Kennedy R.L.
- DAVIES R. see Kennedy R.L.
- DAVIES T.F. see Kendler D.L.
- DAVIS T.M.E., PUKRITTAYAKAMEE S., SUPANARANOND W., LOOAREESUWAN S., KRISHNA S., NAGACHINTA B., TURNER R.C. & WHITE N.J. Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria, 739
- DAWSON J.M. see Barnett P.S.
- DE BOER H. see Roelfsema F.
- DE BRUYN R. see Hague W.H.
- DE LONGUEVILLE M. see Mahler C.
- DEL BALZO P., SALVATORI R., CAPPA M. & GERTNER J.M. Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition, 605
- DELEMARRE-VAN DE WAAL H.A. see Wennink J.M.B.
- DIEGUEZ C. see Leal-Cerro A.
- DIEZGUEZ C. see Peñalva A.
- DOCHERTY K. see Akbari M.T.
- DOGA M. see Giustina A.
- DONNET M.L., HOWIE P.W., MARNIE M., COOPER W. & LEWIS M. Return of ovarian function following spontaneous abortion, 13
- DOWSETT M. see Maouris P.
- DUFFY M.J. see Cronin C.
- DUNAIF A. see Graf M.J.
- DUNGER D.B. see Edge J.A.
- EDEN J.A. see Holly J.M.P.
- EDGE J.A., MATTHEWS D.R. & DUNGER D.B. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics, 729
- EDMONDS D.K. see Maouris P.
- ELSTEIN M. see Golland I.M.
- ELSTEIN M. see Whitehouse R.W.
- ESIRI M.M. see Burke C.W.
- ESTOUR B., PUGEAT M., LANG F., LEJEUNE H., BROUTIN F., PELLET J., ROUSSET H. & TOURNIAIRE J. Rapid escape of cortisol from suppression in response to i.v. dexamethasone in anorexia nervosa, 45
- FAGIUS J., WESTERMARK K. & KARLSSON A. Baroreflex-governed sympathetic outflow to muscle vasculature is increased in hypothyroidism, 177
- FARMER M. see Akbari M.T.
- FINGSCHIEDT U. see Jockenhövel F.
- FITCH N.J. see Akbari M.T.
- FRANKS S. see Mason H.D.
- FRITSCHKA E. see Vogel H.-P.
- FRÖLICH M. see Roelfsema F.
- GADIR A.A., MOWAFI R.S., ALNASER H.M.I., ALRASHID A.H., ALONEZI O.M. & SHAW R.W. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease, 585
- GARCIA-LUNA P.P. see Leal-Cerro A.

- GAZTAMBIDE S. see Peñalva A.
- GEDIK O. see Bayraktar M.
- GERTNER J.M. see del Balzo P.
- GIADOM C.G. see Weaver J.U.
- GIBBS C. see Lunt H.
- GIRAUD P. see Malt  se J.-Y.
- GIRELLI A. see Giustina A.
- GIUSTINA A., BODINI C., BOSSONI S., DOGA M., GIRELLI A., PIZZOCOLO G. & WEHRENBURG W.B. Effects of calcitonin on GH response to pyridostigmine in combination with hGHRH(1-29)NH<sub>2</sub> in normal adult subjects, 375
- GJ  RUP T. see Jarl  v A.E.
- GOLLAND I.M., VAUGHAN WILLIAMS C.A., SHALET S.M., LAING I. & ELSTEIN M. Glucagon in women with polycystic ovary syndrome (PCO): relationship to abnormalities of insulin and androgens, 645
- GRAF M.J., RICHARDS C.J., BROWN V., MEISSNER L. & DUNAIF A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women, 119
- GRANT D.B. see Hague W.H.
- GRIFFITHS H. see Kennedy R.L.
- GROSSMAN A. see Ross R.J.M.
- HAGUE W.H., ADAMS J., RODDA C., BROOK C.G.D., DE BRUYN R., GRANT D.B. & JACOBS H.S. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives, 501
- HAJIME NAWATA see Masao Ohashi
- HANLEY D.A. see Pasiecka J.L.
- HANSEN J.M. see Jarl  v A.E.
- HARA T. see Tamai H.
- HARRIS A. see Mahler C.
- HEGED  S L. see Jarl  v A.E.
- HIDAKA A. see Tamai H.
- HILLIER S.G. A role for epidermal growth factor in the follicular paracrine system?, 427
- HILLIER S.G. see Reddi K.
- HILSTED L. see Andersen H.  .
- HIMATHONGKAM T. see Rajatanavin R.
- HINDMARSH P.C. see Suri D.
- HOFF M. see Caron Ph.
- HOFFMAN J. see Allolio B.
- HOLLY J.M.P. see Conway G.S.
- HOLLY J.M.P. see Weaver J.U.
- HOLLY J.M.P., EDEN J.A., ALAGHBAND-ZADEH J., CARTER G.D., JEMMOT R.C., CIANFARANI S., CHARD T. & WASS J.A.H. Insulin-like growth factor binding proteins in follicular fluid from normal dominant and cohort follicles, polycystic and multicystic ovaries, 53
- HOWIE P.W. see Donnet M.L.
- HOYLAND J. see Levy A.
- HUHTANIEMI I.T. see Kujala U.M.
- HVID-JACOBSEN K. see Jarl  v A.E.
- IGOE D. see Cronin C.
- ILES R.K., LEE C.L., OLIVER R.T.D. & CHARD T. Composition of intact hormone and free subunits in the human chorionic gonadotrophin-like material found in serum and urine of patients with carcinoma of the bladder, 355
- ILLINGWORTH P.J., REDDI K., SMITH K. & BAIRD D.T. Pharmacological 'rescue' of the corpus luteum results in increased inhibin production, 323
- JACOBS H.S. see Conway G.S.
- JACOBS H.S. see Hague W.H.
- JANSSENS X. see Taelman P.
- JARL  V A.E., GJ  RUP T., HEGED  S L., HVID-JACOBSEN K., MARVING J. & HANSEN J.M. Observer variation in the scintigraphic diagnosis of solitary cold thyroid lesion, 1
- JAYAWERRA P. see Adami S.
- JEMMOT R.C. see Holly J.M.P.
- JENKINS J.S. see Page S.R.
- JOCKENH  VEL F., FINGSCHIEDT U., KHAN S.A., BEHRE H.M. & NIESCHLAG, E. Bio and immunoactivity of FSH in serum after intramuscular injection of highly purified urinary human FSH in normal men, 573
- JOHNSON M.R., ANDREWS M.A., SECKL J.R. & LIGHTMAN S.L. Effect of naloxone on neurohypophyseal peptide responses to breast feeding and breast stimulation in man, 81
- J  RGENSEN P.E. see Andersen H.  .
- KAHALY G., SCHULER M., SEWELL A.C., BERNHARD G., BEYER J. & KRAUSE U. Urinary glycosaminoglycans in Graves' ophthalmopathy, 35
- KARLSSON A. see Fagius J.
- KASAGI K. see Tamai H.
- KAUFMAN J.M. see Taelman P.
- KENDLER D.L., MARTIN A., MAGNUSSON R.P. & DAVIES T.F. Detection of autoantibodies to recombinant human thyroid peroxidase by sensitive enzyme immunoassay, 751
- KENNEDY R.L., SHERIDAN E., DARNE J., GRIFFITHS H., DAVIES R., PRICE A. & COHN M. Thyroid function in choriocarcinoma: demonstration of a thyroid stimulating activity in serum using FRTL-5 and human thyroid cells, 227
- KHAN S.A. see Jockenh  vel F.
- KIRK J.M.W. see Ross R.J.M.
- KOCHUPILLAI N. see Tandon N.
- KOMIYA I. see Takasu N.
- KONGSUKSAI A. see Rajatanavin R.
- KONISHI J. see Tamai H.

- KOPELMAN P.G. see Weaver J.U.  
 KRAUSE U. see Kahaly G.  
 KRISHNA S. see Davis T.M.E.  
 KROLL M. see Vogel H.-P.  
 KUJALA U.M., ALEN M. & HUHTANIEMI I.T.  
 Gonadotrophin-releasing hormone and human chorionic gonadotrophin tests reveal that both hypothalamic and testicular endocrine functions are suppressed during acute prolonged physical exercise, 219  
 KUMA K. see Tamai H.  
 KUMAGI L.F. see Tamai H.  
 KUSCHE M. see Allolio B.  
 LAESSLE R.G. see Pirke K.M.  
 LAI K.N. see Chow C.C.  
 LAING I. see Golland I.M.  
 LANCRANJAN I. see Schettini G.  
 LANG F. see Estour B.  
 LEAL-CERRO A., PEREIRA J.L., GARCIA-LUNA P.P., ASTORGA R., CORDIDO F., CASANUEVA F.F. & DIEGUEZ C. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome, 291  
 LEE C.L. see Iles R.K.  
 LEJEUNE H. see Estour B.  
 LEUNG J.C.K. see Chow, C.C.  
 LEVY A., LIGHTMAN S.L., HOYLAND J. & MASON W.T. Inositol phospholipid turnover and intracellular  $Ca^{2+}$  responses to thyrotrophin-releasing hormone and arginine vasopressin in pituitary corticotroph and somatotroph adenomas, 73  
 LEWIS, M. see Donnet M.L.  
 LI ZHANG see Weetman A.P.  
 LIGHTMAN S.L. see Johnson M.R.  
 LIGHTMAN S.L. see Levy A.  
 LINDHOLM J. see Åström C.  
 LINTON E.A. see Allolio B.  
 LITTLE M.D., SHALET S.M., BEARDWELL C.G., AHMED S.R. & SUTTON M.L. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease, 445  
 LO CASCIO V. see Adami S.  
 LOCHE S., PINTUS S., CELLA S.G., BOGHEN M., VANNELLI S., BENSO L., MULLER E.E., CORDA R. & PINTOR C. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children, 187  
 LOMBARDI G. see Schettini G.  
 LOOAREESUWAN S. see Davis T.M.E.  
 LOUVET J.P. see Caron Ph.  
 LOUVET J.P. see Ribot C.  
 LUNDGREN E. & CHRISTENSEN S.B. Decreasing incidence of thyrotoxicosis in an endemic goitre inland area of Sweden, 133  
 LUNENFELD B. see Shoham (Schwartz) Z.  
 LUNT H., TUCKER A.J., BULLEN H., GIBBS C. & WILKIN T.J. Overnight urinary growth hormone measurement in the diagnosis of acromegaly, 205  
 MACCABE J.J. see Barnett P.S.  
 MAGNUSSON R.P. see Kendler D.L.  
 MAHLER C., VERHELST J., DE LONGUEVILLE M. & HARRIS A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide, 261  
 MALTÈSE J.-Y., MONGE G., GIRAUD P., SALERS P., OUAÏK L'H., PELEN F. & OLIVER C. Characterization of an  $\alpha$ -amidating activity in a human pancreatic tumour secreting vasoactive intestinal peptide (VIP), 467  
 MAOURIS P., DOWSETT M., ROSE G., EDMONDS D.K., ROTHWELL C. & ROBERTSON W.R. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis, 539  
 MARGARA T. see Mason H.D.  
 MARKS, V. see Teale J.D.  
 MARNIE M. see Donnet M.L.  
 MARTIN A. see Kendler D.L.  
 MARVING J. see Jarlov A.E.  
 MASAFUMI HAJI see Masao Ohashi  
 MASAO IGARASHI see Masao Ohashi  
 MASAO OHASHI, YOSHIHISA HASEGAWA, MASAFUMI HAJI, MASAO IGARASHI & HAJIME NAWATA. Production of immunoreactive inhibin by a virilizing ovarian tumour (Sertoli-Leydig tumour), 613  
 MASON H.D., MARGARA R., WINSTON R.M.L., BEARD R.W., REED M.J. & FRANKS S. Inhibition of oestradiol production by epidermal growth factor in human granulosa cells of normal and polycystic ovaries, 51  
 MASON W.T. see Levy A.  
 MATTHEWS D.R. see Edge J.A.  
 MCGREGOR A.M. Autoantibodies to the TSH receptor in patients with autoimmune thyroid disease, 683  
 MCGREGOR A.M. see Barnett P.S.  
 MCKENNA T.J. see Cronin C.  
 MCLACHLAN R.I. see Nakajima S.T.  
 MCNEILLY A.S. see Reddi K.  
 MEHRA N.K. see Tandon N.  
 MEISSNER L. see Graf M.J.  
 MEROLA B. see Schettini G.  
 MESSINIS I.E. & TEMPLETON A. In-vivo bioactivity of gonadotrophin surge attenuating factor (GnSAF), 213  
 MIAN M. see Adami S.  
 MILETTO P. see Schettini G.  
 MONGE G. see Maltèse J.-Y.

- MORITA T. see Tamai H.  
 MORRIS C. see Burke C.W.  
 MOWAFI R.S. see Gadir A.A.  
 MULLER E.E. see Loche S.
- NAGACHINTA B. see Davis T.M.E.  
 NAGASAWA Y. see Takasu N.  
 NAGATAKI S. see Tamai H.  
 NAKAGAWA M. see Takasu N.  
 NAKAJIMA S.T., McLACHLAN R.I., COHEN N.L., CLIFTON D.K., BREMNER W.J. & SOULES M.R.  
 The immunoreactive inhibin secretion pattern in the midluteal phase: relationships with luteinizing hormone and progesterone, 709  
 NIESCHLAG E. see Jockenhövel F.  
 NOONAN K. see Weaver J.U.  
 NUSSEY S.S. see Page S.R.
- O'RIORDAN J.L.H. see Adami S.  
 OLBRICHT T. see Benker G.  
 OLIVER C. see Malt  se J.-Y.  
 OLIVER R.T.D. see Iles R.K.  
 OUAFIK L'H. see Malt  se J.-Y.
- PAGE S.R., PETERSON D.B., CROSBY S.R., ANG V.T.Y., WHITE A., JENKINS J.S. & NUSSEY S.S. The responses of arginine vasopressin and adrenocorticotrophin to nausea induced by ipecacuanha, 761  
 PARIENTE C. see Shoham (Schwartz) Z.  
 PARRA H.J. see Caron Ph.  
 PASIEKA J.L., ANDERSEN M.A. & HANLEY D.A.  
 Familial benign hypercalcaemia: hypercalciuria and hypocalciuria in affected members of a small kindred, 429  
 PEDERSEN S.A. see   str  m C.  
 PELEN F. see Malt  se J.-Y.  
 PELLET J. see Estour B.  
 PE  ALVA A., GAZTAMBIDE S., VAZQUEZ J.A., DIEZGUEZ C. & CASANUEVA F.F. Role of cholinergic muscarinic pathways of the free fatty acid inhibition of GH responses to GHRH in normal men, 171  
 PEREIRA J.L. see Leal-Cerro A.  
 PESTELL R.G., ALFORD F., RAMOS R., SAWYER S., BEST J.D. & WARD G. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in thyrotoxicosis: a minimal model analysis, 481  
 PESTELL R.G., BEST J.D. & ALFORD F.P. Lymphocytic hypophysitis. The clinical spectrum of the disorder and evidence for an autoimmune pathogenesis, 457  
 PETERSON D.B. see Page S.R.  
 PINTOR C. see Loche S.  
 PINTUS S. see Loche S.
- PIRKE K.M., SCHWEIGER U., BROOCKS A., TUSCHL R.J. & LAESSLE R.G. Luteinizing hormone and follicle stimulating hormone secretion patterns in female athletes with and without menstrual disturbances, 345  
 PIZZOCOLO G. see Giustina A.  
 POUILLES J.M. see Ribot C.  
 PRICE A. see Kennedy R.L.  
 PRINGLE P.J. see Suri D.  
 PUGEAU M. see Estour B.  
 PUKRITTAYAKAMEE S. see Davis T.M.E.
- QUABBE H.-J. see Vogel H.-P.
- RAIDA M. see Benker G.  
 RAJATANAVIN R., CHAILURKIT L-O., KONGSUKSAI A., TEERAVANINTHORN U. & HIMATHONGKAM T.  
 The effect of amiodarone on the control of hyperthyroidism by propylthiouracil, 193  
 RAMOS R. see Pestell R.G.  
 RAMSDEN D.B. see Akbari M.T.  
 RASMUSSEN D.D. see Rossmann W.G.  
 REDDI K. see Illingworth P.J.  
 REDDI K., WICKINGS E.J., MCNEILLY A.S., BAIRD D.T. & HILLIER S.G. Circulating bioactive follicle stimulating hormone and immunoreactive inhibin levels during the normal human menstrual cycle, 547  
 REED M.J. see Mason H.D.  
 REINHARDT W. see Benker G.  
 REINWEIN D. see Benker G.  
 RIBOT C., TREMOLIERES F., POUILLES J.M. & LOUVET J.P. Bone mineral density and thyroid hormone therapy, 143  
 RICHARDS C.J. see Graf M.J.  
 RICHARDS G.P. see Boultonwood J.  
 ROBERTSON W.R. see Maouris P.  
 RODDA C. see Hague W.H.  
 ROELFSEMA F., DE BOER H. & FR  LICH M. The influence of octreotide treatment on pulsatile growth hormone release in acromegaly, 297  
 ROSE G. see Maouris P.  
 ROSS R.J.M., KIRK J.M.W., TSAGARAKIS S., TRAINER P.J., CICCARELLI E., TOUZEL R., GROSSMAN A., SAVAGE M.O. & BESSER G.M. Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion, 239  
 ROSSINI M. see Adami S.  
 ROSSMAN W.G., SWARTZ W.H., TUEROS V.S., YEN S.S.C. & RASMUSSEN D.D. Pulsatile GnRH-stimulated LH release from the human fetal pituitary *in vitro*: sex-associated differences, 719  
 ROTHWELL C. see Maouris P.  
 ROUSSET H. see Estour B.

- SALERS P. see Malt   J.-Y.  
 SALVATORI R. see del Balzo P.  
 SATO A. see Takasu N.  
 SAVAGE M.O. see Ross R.J.M.  
 SAWYER S. see Pestell R.G.  
 SCHETTINI G., LOMBARDI G., MEROLA B., COLAO A., MILETTO P., CARUSO E. & LANCRIANJAN I. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR), 161  
 SCHOEMAKER H. see Wennink J.M.B.  
 SCHOEMAKER J. see Wennink J.M.B.  
 SCHOEMAKER R. see Wennink J.M.B.  
 SCHULER M. see Kahaly G.  
 SCHULTE H.M. see Allolio B.  
 SCHULTE H.M., WEISNER D. & ALLOLIO B. The corticotrophin releasing hormone test in late pregnancy: lack of adrenocorticotrophin and cortisol response, 99  
 SCHWEIGER U. see Pirke K.M.  
 SECKL J.R. see Johnson M.R.  
 SEWELL A.C. see Kahaly G.  
 SHALET S.M. see Golland I.M.  
 SHALET S.M. see Little M.D.  
 SHARPE R.M. Review: Intratesticular control of steroidogenesis, 787  
 SHAW R.W. see Gadir A.A.  
 SHEPPARD M.C. see Akbari M.T.  
 SHERIDAN E. see Kennedy R.L.  
 SHINE B. see Weetman A.P.  
 SHOHAM (SCHWARTZ) Z., BORENSTEIN R., LUNENFELD B. & PARIENTE C. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles, 271  
 SMITH K. see Illingworth P.J.  
 SOULES M.R. see Nakajima S.T.  
 SUPANARANOND W. see Davis T.M.E.  
 SURJ D., HINDMARSH P.C., BRAIN C.E., PRINGLE P.J. & BROOK C.G.D. The interaction between clonidine and growth hormone releasing hormone in the stimulation of growth hormone secretion in man, 399  
 SUTTON M.L. see Little M.D.  
 SWARTZ W.H. see Rossmann W.G.  
 TAMAI H., KASAGI K., HARA T., HIDAKA A., MORITA T., KUMA K., KONISHI J., KUMAGI L.F. & NAGATAKI S. Follow-up study of thyroid stimulating-blocking antibodies in hypothyroid patients, 699  
 TANDON N., MEHRA N.K., TANEJA V., VAIDYA M.C. & KOCHUPILLAI N. HLA antigens in Asian Indian patients with Graves' disease, 21  
 TANEJA V. see Tandon N.  
 TEALE J.D. & MARKS V. Inappropriately elevated plasma insulin-like growth factor II in relation to suppressed insulin-like growth factor I in the diagnosis of non-islet cell tumour hypoglycaemia, 87  
 TEERAVANINTHORN U. see Rajatanavin R.  
 TELATAR F. see Bayraktar M.  
 TEMPLETON A. see Messinis I.E.  
 TOSCANO V. see Balducci R.  
 TOURNIAIRE J. see Estour B.  
 TOUZEL R. see Ross R.J.M.  
 TRAINER P.J. see Ross R.J.M.  
 TREMOLLIERS F. see Ribot C.  
 TSAGARAKIS S. see Ross R.J.M.  
 TUCKER A.J. see Lunt H.  
 TUEROS V.S. see Rossmann W.G.  
 TURNER R.C. see Davis T.M.E.  
 TUSCHL R.J. see Pirke K.M.  
 USMAN A. see Bayraktar M.  
 VAIDYA M.C. see Tandon N.  
 VAN'T VERLAAT J.W., CROUGHS R.J.M. & BROWNELL J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV205-502, 619  
 VANDECAUTER H. see Taelman P.  
 VANNELLI S. see Loche S.  
 VAUGHAN WILLIAMS C. Ovarian electrocautery in the treatment of polycystic ovary syndrome, 569  
 VAUGHAN WILLIAMS C.A. see Golland I.M.  
 VAUGHAN WILLIAMS C.A. see Whitehouse R.W.  
 VAZQUEZ J.A. see Pe  alva A.  
 VERHELST J. see Mahler C.  
 VERMEULEN A. see Taelman P.  
 VIRDEE S. see Weaver J.U.  
 VOGEL H.-P., KROLL M., FRITSCHKA E. & QUABBE H.-J. Twenty-four hour profiles of growth hormone, prolactin and cortisol in the chronic vegetative state, 631  
 WAGNER R. see Benker G.  
 WARD G. see Pestell R.G.  
 WASS J.A.H. see Conway G.S.  
 WASS J.A.H. see Holly J.M.P.  
 WASS J.A.H. see Weaver J.U.

- WEAVER J.U., HOLLY J.M.P., KOPELMAN P.G., NOONAN K., GIADOM C.G., WHITE N., VIRDEE S. & WASS J.A.H. Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity, 415
- WEBB S. see Weetman A.P.
- WEETMAN A.P., LI ZHANG, WEBB S. & SHINE B. Analysis of HLA-DQB and HLA-DPB alleles in Graves' disease by oligonucleotide probing of enzymatically amplified DNA, 65
- WEHRENBURG W.B. see Giustina A.
- WEISNER D. see Schulte H.M.
- WELLS J.E. see Brownlie B.E.W.
- WENNINK J.M.B., DELEMARRE-VAN DE WAAL H.A., SCHOEMAKER R., SCHOEMAKER H. & SCHOEMAKER J. Luteinizing hormone and follicle stimulating hormone secretion patterns in girls throughout puberty measured using highly sensitive immunoradiometric assays, 333
- WESTERMARK K. see Fagius J.
- WHITE A. see Page S.R.
- WHITE N. see Weaver J.U.
- WHITE N.J. see Davis T.M.E.
- WHITEHOUSE R.W., ADAMS J.E., BANCROFT K., VAUGHAN WILLIAMS C.A. & ELSTEIN M. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis, 365
- WICKINGS E.J. see Reddi K.
- WILKIN T.J. see Lunt H.
- WILLIAMS E.D. see Boultonwood J.
- WINKELMANN W. see Allolio B.
- WINSTON R.M.L. see Mason H.D.
- WYNFORD-THOMAS D. see Boultonwood J.
- YAMADA T. see Takasu N.
- YEN S.S.C. see Rossmanith W.G.
- YOSHIHISA HASEGAWA see Masao Ohashi

Subject index to Volume 33

- Abortion  
spontaneous and ovarian function, 13
- Acromegaly  
urinary GH in diagnosis, 205  
effect of octreotide on GH release in, 297
- ACTH and AVP responses to nausea, 761
- Amiodarone  
effect on control of hyperthyroidism by propylthiouracil, 193
- Androgens  
in girls with hypertrichiosis, 407  
in PCO, relation to glucagon and insulin, 645
- Anorexia nervosa  
cortisol escape from dexamethasone suppression, 45
- Autoantibodies to rh thyroid peroxidase  
sensitive enzyme immunoassay, 751
- Autoimmune  
pathogenesis of lymphocytic hypophysitis, 457  
thyroid disease, autoantibodies to the TSH receptor in, 683
- AVP and ACTH responses to nausea, 761
- Baroreflex  
and sympathetic outflow in hypothyroidism, 177
- Bisphosphonate  
effect on Ca-PTH feedback in hyperparathyroidism, 391
- Bladder  
composition of hCG in carcinoma of, 355
- Bone  
mineral content in women with euthyroid goitre treated with thyroid hormone, 107  
mineral density and thyroid hormone therapy, 143  
effect of nafarelin and danazol in endometriosis on, 365  
Ca-PTH feedback in hyperparathyroidism, effects of bisphosphonate on, 391  
osteoporosis, 653
- Breast feeding and stimulation, effect of naloxone on neurohypophyseal peptide, 81
- Bromocriptine  
long-acting, and suppression of PRL and shrinkage of prolactinomas, 161
- CAH  
and PCO, 501
- due to 21-hydroxylase deficiency, management, 559
- Calcium  
response to TRH, GnRH and AVP in pituitary corticotroph and somatotroph adenomas, 73  
-PTH feedback in hyperparathyroidism, effect of bisphosphonate on, 391
- Calcitonin  
effect on GH response to pyridostigmine with hGHRH, 375  
and CGRP expression in medullary thyroid cancer, 381
- Carbimazole  
and IL-2 receptor in Graves' disease, 317
- Children  
effect of galanin on GHRH-induced GH in obese, 187  
LH and FSH secretion pattern in girls by IRMA, 333  
hypertrichiosis and androgens in girls, 407  
management of CAH in, 559  
dawn phenomenon (insulin requirement) and overnight GH in diabetic, 729
- Cholesterol  
decreased in hypothyroidism, effect of L-thyroxine, 519
- Cholinergic muscarinic pathways  
role in FFA inhibition of GH responses to GHRH, 171
- Choriocarcinoma  
thyroid function in, 227
- Clomiphene citrate  
and hormones in (non)conception cycles, 271
- Clonidine  
with GHRH and GH secretion in men, 399
- Corpus luteum  
'rescue' and inhibin production, 323
- Cortisol  
suppression by dexamethasone, rapid escape from in anorexia nervosa, 45  
patterns, pregnancy and CRH, 279  
in vegetative state, 631
- CRH  
in pregnancy, lack of ACTH and cortisol response, 99  
and cortisol patterns in pregnancy, 279
- Cushing's disease/syndrome  
overnight dexamethasone screening, 27



- effect of pyridostigmine on GH response to GHRH in, 291
- pituitary irradiation for, 445
- transsphenoidal surgery: outcome, 525
- TSH secretion and glucocorticoid, diabetes, goitre and 'sick euthyroid syndrome', 435
- CV205-502
  - non-ergot dopamine agonist reduces prolactin-oma, 307
  - and macroprolactinomas, 619
- Danazol
  - effect on bone mass in endometriosis, 365
  - effect on activity of LH in endometriosis, 539
- Dexamethasone test
  - screening for Cushing's disease, 27
  - escape from cortisol suppression in anorexia nervosa, 45
- Diabetes
  - dawn phenomenon (insulin requirement) and overnight GH in adolescents, 729
  - and TSH secretion in Cushing's syndrome, 777
- Endometriosis
  - effect of nafarelin and danazol on bone mass, 365
  - effect of danazol and goserelin on LH activity in, 539
- Enzyme immunoassay
  - for autoantibodies to rh thyroid peroxidase, 751
- Epidemiology
  - of thyrotoxicosis in New Zealand, 249
  - of thyrotoxicosis in Sweden, 133
- Epidermal growth factor
  - in follicular paracrine system, 427
  - inhibition of oestradiol production in granulosa cells, 511
- Exercise
  - suppresses hypothalamic and testicular function shown by GnRH and hCG tests, 219
  - LH and FSH secretion patterns in female athletes, 345
- Fetal pituitary
  - GnRH-stimulated LH release in, sex-associated differences, 719
- FFA
  - inhibition of GH response to GHRH, 171
- Follicular paracrine system
  - epidermal growth factor in, 427
- FSH
  - secretion pattern in girls by IRMA, 333
  - secretion pattern in female athletes, 345
  - levels in menstrual cycle, 547
  - bio and immuno activity after i.m. injection in men, 573
- Galanin
  - effect on GHRH-induced GH in obese children, 187
- Genetics
  - thyroxine-binding prealbumin gene polymorphism, 155
  - calcitonin and CGRP expression in medullary thyroid cancer, 381
  - hypercalcaemia and hypocalciuria, 429
  - PCO and CAH, 501
- GH
  - response to GHRH, inhibition by FFA, 171
  - response to GHRH, effect of galanin in obese children, 187
  - urinary in acromegaly diagnosis, 205
  - response to GHRH, effect of pyridostigmine in Cushing's syndrome, 291
  - effect of octreotide on in acromegaly, 297
  - response to pyridostigmine with GHRH, effect of calcitonin on, 375
  - response to clonidine with GHRH in men, 399
  - influence on sleep with GH deficiency, 495
  - sex-induced inhibition, not reversed by pyridostigmine, 605
  - in vegetative state, 631
- GHRH
  - response inhibition by FFA, 171
  - and GH-insufficient children, 239
  - and GH response in Cushing's syndrome, effect of pyridostigmine, 291
  - with pyridostigmine, effect of calcitonin on GH response, 375
  - with clonidine, effect on GH secretion in men, 399
- Glucagon
  - in PCO, relation to insulin and androgens, 645
- Glucose
  - disposal in thyrotoxicosis, minimal model analysis, 481
  - metabolism in quinine-treated malaria, 739
- Glycosaminoglycans
  - in Graves' ophthalmopathy, 35
- GnRH
  - shows suppression of hypothalamic and testicular function by exercise, 219
- GnSAF bioactivity, 213
- Goitre
  - euthyroid, BMC in women treated with thyroid hormone, 107
  - endemic, incidence of thyrotoxicosis in Sweden, 133
  - and TSH secretion in Cushing's syndrome, 777
- Goserelin
  - effect on LH activity in endometriosis, 539
- Granulosa cells
  - inhibition of oestradiol production by EGF in, 511

- Graves' disease  
  HLA antigens in Indians, 21  
  analysis of HLA alleles in, 65  
  IL-2 receptor and carbimazole in, 317  
  following hypothyroidism due to Hashimoto's disease, 687
- Graves' ophthalmopathy  
  urinary glycosaminoglycans in, 35
- Hashimoto's disease  
  Graves' disease following hypothyroidism due to, 687
- hCG  
  shows suppression of hypothalamic and testicular function by exercise, 219  
  and thyroid function, 227  
  'rescue' of corpus luteum and inhibin production, 323  
  composition in carcinoma of bladder, 355  
  HLA alleles in Graves' disease, analysis, 65
- HLA antigens  
  in Indian patients with Graves' disease, 21
- Hyperandrogenaemia  
  effect on lipid and lipoprotein in women, 119
- Hypercalcaemia  
  familial, and hypocalciuria, 429  
  in hyperparathyroidism, effect of bisphosphonate, 391
- Hyperinsulinaemia  
  effect on lipid and lipoprotein in women, 119
- Hyperparathyroidism  
  Ca-PTH feedback: effects of bisphosphonate, 391
- Hyperthyroidism  
  effect of amiodarone on control by propylthiouracil, 193  
  and hCG, 227  
  carbimazole and IL-2 receptor in Graves' disease, 317
- Hypertrichiosis  
  androgens in prepubertal girls, 407
- Hypocalciuria and familial hypercalcaemia, 429
- Hypoglycaemia  
  non-islet cell tumour, IGF-I and -II levels, 87
- Hypothalamus  
  suppression in exercise shown by GnRH and hCG tests, 219
- Hyperthyroidism  
  sympathetic outflow and baroreflex, 177  
  decreased cholesterol in, effect of L-thyroxine, 519  
  due to Hashimoto's disease, Graves' disease following, 687  
  thyroid stimulating-blocking antibodies in, 699
- IGF  
  I and II levels in diagnosis of non-islet cell tumour hypoglycaemia, 87
- I in PCO, 593
- IGFBP  
  in follicular fluid from normals, PCO and MCO, 53  
  and SHBG in obesity, 415  
  in PCO, 593
- IL-2 receptor in hyperthyroid Graves' disease, and carbimazole, 317
- Indians  
  HLA antigens in Graves' disease, 21
- Inhibin  
  production and corpus luteum 'rescue', 323  
  levels in menstrual cycle, 547  
  production by virilizing ovarian tumour, 613  
  secretion in midluteal phase: relations with LH and progesterone, 709
- Inositol phospholipid  
  turnover in pituitary corticotroph and somatotroph adenomas, 73
- Insulin  
  secretion and sensitivity in thyrotoxicosis, a minimal model analysis, 481  
  in PCO, 593  
  in PCO, relation to glucagon and androgens, 645
- IRMA  
  for LH and FSH secretory pattern in girls, 333
- LH  
  secretion pattern in girls by IRMA, 333  
  secretion pattern in female athletes, 345  
  in PCO, 593
- Lymphocytic hypophysitis  
  autoimmune pathogenesis, 457
- Malaria  
  glucose metabolism in quinine-treated, 739
- Medullary thyroid carcinoma  
  treatment with octreotide, 261  
  calcitonin and CGRP expression in, 381
- Melatonin metabolite, 435
- Men  
  exercise and hypothalamic and testicular function suppression, GnRH and hCG tests, 219  
  effect of clonidine with GHRH on GH secretion in, 399  
  FSH bio and immunoactivity after i.m. injection, 573  
  intratesticular control of steroidogenesis, 787
- MEN-1  
  screening for, with pituitary adenoma, 771
- Muscle  
  baroreflex-governed sympathetic outflow in hypothyroidism, 177
- Nafarelin  
  effect on bone mass in endometriosis, 365

- Naloxone  
  effect on neurohypophyseal peptide responses to breast feeding and stimulation, 81
- Nausea  
  AVP and ACTH response, 761
- Neurohypophyseal peptide  
  effect of naloxone on in breast feeding and stimulation, 81
- New Zealand  
  epidemiology of thyrotoxicosis in, 249
- Obesity  
  effect on lipid and lipoprotein in women, 119  
  effect of galanin on GHRH-induced GH in children, 187  
  SHBG and IGFBP-I in, 415
- Observer variation  
  scintigraphic diagnosis of thyroid lesions, 1
- Ovarian function  
  following spontaneous abortion, 13
- Octreotide  
  treatment of medullary thyroid carcinoma, 261  
  effect on GH in acromegaly, 297
- Oestradiol production  
  inhibition by EGF in granulosa cells, 511
- Osteoporosis review, 653
- Ovarian electrocautery  
  in PCO, 569  
  versus hMG and FSH in PCO, 585
- Ovarian tumour  
  inhibin production by virilizing, 613
- Pancreatic tumour  
  secreting  $\alpha$ -amidating activity and VIP in WDHA syndrome, 467
- Paracrine system  
  follicular, epidermal growth factor in, 427  
  intratesticular and steroidogenesis, 782
- PCO  
  IGFBP in follicular fluid, 53  
  with CAH, and relatives, 501  
  ovarian electrocautery or hormone therapy in, 569, 585  
  effect of LH, insulin, IGF-I and IGFBP-I in, 593  
  glucagon in, relation to insulin and androgens, 645
- Pituitary  
  fetal, GnRH-stimulated LH release in, sex-associated differences, 719
- Pituitary adenomas  
  inositol phospholipid and  $\text{Ca}^{2+}$  responses to TRH, GnRH  
  and AVP in, 73  
  screening for MEN-1, 771
- Pregnancy  
  CRH test: lack of ACTH and cortisol response, 99  
  and clomiphene citrate therapy, 271  
  cortisol patterns and CRH, 279
- PRL  
  suppression and long-acting bromocriptine, 161  
  in vegetative state, 631
- Prolactinomas  
  shrinkage and long-acting bromocriptine, 161  
  reduced by CV205-502 non-ergot dopamine agonist, 307  
  macro, treatment by CV205-502, 619
- Propylthiouracil  
  effect of amiodarone on control of hyperthyroidism by, 193
- Pyridostigmine  
  effect on GH response to GHRH in Cushing's syndrome, 291  
  with hGHRH, effect of calcitonin on GH response, 375  
  not reverse sex-induced GH inhibition, 605
- Quinine  
  treated malaria, glucose metabolism in, 739
- Radioiodine  
  effect on thyroid C cells, 625
- Radiotherapy  
  of pituitary in Cushing's disease, 445
- Scintigraphy of thyroid lesions, 1
- Screening  
  overnight dexamethasone for Cushing's disease, 27
- Sertoli-Leydig tumour  
  inhibin production by, 613
- SHBG and IGFBP-I in obesity, 415
- Sick euthyroid syndrome  
  and TSH secretion in Cushing's syndrome, 777
- Sleep  
  influence of GH on, 495
- Spontaneous abortion and ovarian function, 13
- Steroidogenesis  
  intratesticular control of, 787
- 6-Sulphatoxymelatonin, 435
- Sympathetic  
  baroreflex-governed in hypothyroidism
- Testes  
  suppression in exercise shown by GnRH and hCG tests, 219  
  control of steroidogenesis in, 787
- Testosterone  
  intratesticular, and steroidogenesis, 787

- Thyroid  
  scintigraphy, 1  
  function in choriocarcinoma, 227  
  effect of radioiodine on C cells, 625  
  disease, autoimmune autoantibodies to TSH  
    receptor in, 683  
Thyroid stimulating-blocking antibodies  
  in hypothyroidism, 699  
Thyrotoxicosis  
  in endemic goitre in Sweden, 133  
  in New Zealand, 249  
  insulin secretion and sensitivity and glucose dis-  
    posal, minimal model analysis, 481  
Throxine  
  therapy and BMD, 143  
  therapy and HDL cholesterol, 519  
Thyroxine-binding prealbumin gene  
  polymorphism, 155  
Transsphenoidal surgery  
  outcome in Cushing's disease, 525  
TSH receptor  
  autoantibodies to in autoimmune thyroid disease,  
    683  
Vegetative state  
  GH, PRL and cortisol profiles in, 631  
WDHA syndrome  
  pancreatic tumour secreting  $\alpha$ -amidating activity  
    and VIP, 467  
Women  
  ovarian function after spontaneous abortion, 13  
  anorexia nervosa and cortisol suppression by  
    dexamethasone, 45  
  IGFBP in normals, PCO and MCO follicular  
    fluid, 53  
  effect of naloxone on neurohypophyseal peptide  
    response to breast feeding and stimulation,  
      81  
  CRH test in pregnancy, lack of ACTH and  
    cortisol response, 99  
  BMC in euthyroid goitre treated with thyroid  
    hormone, 107  
  effect of hyperandrogenaemia, hyperinsulinaemia  
    and obesity on lipid and lipoproteins in, 119  
  GnSAF bioactivity, 213  
  clomiphene citrate treatment and (non) concep-  
    tion, 271  
  cortisol patterns, pregnancy and CRH, 279  
  LH and FSH secretion pattern in girls by IRMA,  
    333  
  LH and FSH secretion patterns in athletes, 345  
  nafarelin and danazol in endometriosis, effect on  
    bone mass, 365  
  androgens and hypertrichiosis in girls, 407  
  SHBG and IGFBP-1 in obese, 415  
  epidermal growth factor in follicular paracrine  
    system, 427  
  PCO and CAH, 501  
  inhibition of oestradiol production by EGF in  
    granulosa cells, 511  
  effect of danazol and goserelin on LH activity in  
    endometriosis, 539  
  FSH and inhibin levels in menstrual cycle, 547  
  ovarian electrocautery or hormone therapy in  
    PCO, 569, 585  
  LH, insulin, IGF-I and IGFBP-1, 593  
  inhibin production by virilizing ovarian tumour,  
    613  
  glucagon in PCO, relation to insulin and andro-  
    gens, 645  
  osteoporosis, 653  
  inhibin secretion in midluteal phase, relations to  
    LH and progesterone, 709

